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ABSTRACT: 
An improved ability to direct and control biomolecular interactions in living cells would impact 
on synthetic biology. A key issue is the need to introduce interacting components that act 
orthogonally to endogenous proteomes and interactomes.  Here we show that low-complexity, 
de novo designed protein-protein-interaction (PPI) domains can substitute for natural PPIs and 
guide engineered protein-DNA interactions in Escherichia coli.  Specifically, we use de novo 
homo- and hetero-dimeric coiled coils to reconstitute a cytoplasmic split adenylate cyclase; to 
recruit RNA polymerase to a promoter and activate gene expression; and to oligomerize both 
natural and designed DNA-binding domains to repress transcription.  Moreover, the stabilities 
of the heterodimeric coiled coils can be modulated by rational design and, thus, adjust the levels 
of gene activation and repression in vivo.  These experiments demonstrate the possibilities for 
using designed proteins and interactions to control biomolecular systems such as enzyme 
cascades and circuits in cells. 
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The advent of synthetic biology has brought an increased demand for protein components of 
reduced size and complexity, which are orthogonal to cellular systems and that function 
according to understood parameters. Protein-protein interactions (PPIs) are one aspect of 
protein function that is amenable to design and manipulation. Moreover, an ability to design 
PPIs completely de novo and predictably would impact broadly in synthetic biology by 
allowing biomolecular interactions and functions to be guided and orchestrated in cells with 
precision and, potentially, without interfering with endogenous proteomes and interactomes.  
Whilst excellent progress has been made on the de novo design and assembly of PPI-mediated 
macromolecular structures in vitro,1-4 less has been done in living cells. Success here would 
allow the targeting of proteins to prescribed cellular regions, the co-localization of enzymes to 
optimize bioproduction, the reconstitution of split proteins to switch enzyme activity on and 
off, and the assembly of completely new structures in cells to act as scaffolds or compartments 
for such processes.5-8 An advantage of targeting PPIs to take control in synthetic biology is that 
the PPI components are usually separable from the downstream activity, and so designed PPIs 
will find applications across many different systems.  
An important example of PPIs in cells is transcription control, where PPI-mediated 
recruitment of components underlies most forms of gene activation.9 Transcription repression 
is also often underpinned by PPIs, either by recruitment of corepressors or because the 
multimerization of the repressor proteins is a prerequisite for DNA binding.10, 11  Indeed, in cell 
and synthetic biology, transcription regulation has provided proof-of-concept systems in which 
to monitor and exploit PPIs within cells.12-15  In their simplest forms, transcription activators 
consist of a DNA-binding domain, which defines the promoter-specificity of its action, and a 
PPI domain that recruits RNA polymerase (RNAP) or an associated factor.14 Bacterial 
repressor proteins are conceptually even simpler, as an isolated DNA-binding domain can 
repress transcription by sterically blocking RNAP binding. However, most natural bacterial 
repressor proteins exist as PPI-dependent multimers. The cooperative binding that results from 
multimerization can be important for the design and function of Gene Regulatory Networks 
(GRNs).16  For both activators and repressors, the affinity of the PPI and of the protein-DNA 
interaction are key parameters that define the behavior of the components within such GRNs.  
One of the best-understood PPI motifs is the -helical coiled coil (CC).17, 18 This 
understanding has led to considerable success in CC design.4, 19, 20  CCs are abundant in nature 
and usually display heptad sequence repeats of hydrophobic (h) and polar (p) amino acids, 
hpphppp (often denoted abcdefg).  These repeating patterns direct the folding of amphipathic 
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α helices, which assemble via their hydrophobic faces to form left-handed rope-like structures 
with two or more helices in parallel or antiparallel orientations.17, 18  The rules that govern 
assembly of CCs have been deciphered. 19-21  In turn, these have enabled the rational design of 
“toolkits” of CC peptides that assemble in homo- or hetero-multimeric complexes predictably 
in vitro.22-27 In one such study from one of our laboratories, the hydrophobic amino acids at 
positions a and d have been varied to create a set of 30-residue peptides that form parallel 
homomeric dimers, trimers and tetramers, which have been characterized to atomic 
resolution.23  These peptides are named CC-Di, CC-Tri and CC-Tet, respectively. A series of 
parallel heterodimeric CCs has also been designed, in which one set of peptides has acidic 
amino acids at the e and g positions and another complementary set has basic residues at the e 
and g sites.24  These CC-Di-A and CC-Di-B peptides do not fold in isolation, but combine when 
mixed to form stable, obligate heterodimers.  Moreover, as CC stability increases with 
increasing chain length, the CC-Di-AB heterodimers can be tuned to give a range of 
dissociation constants that varies over several orders of magnitudes in vitro (Supplementary 
Table S1).24 
As pioneered by Keating and colleagues, natural and synthetic CCs have been shown to 
function effectively as PPIs within transcription activators in yeast and E. coli.25, 28 The design 
and in vivo application of de novo CCs, and particularly CC-based dimers, is increasingly being 
reported.  For example, Hussey and McMillen employ de novo heterodimeric CCs to recruit 
T7 RNA polymerase to Zn-finger DNA-binding domains in E. coli;28 Lee and co-workers  
demonstrate that a de novo heterodimer can be used to recruit enzymes to semi-synthetic 
cytoscaffolds assembled within the cytoplasm of E. coli;7 Chen et al. and Baker describe the 
computational design of helix-loop-helix motifs that combine to make orthogonal four-helix 
bundles that fold and function in E. coli;29 and Fink et al. and Jerala show how designed dimeric 
CCs can drive the complementation of split proteases to implement Boolean logic circuits and 
signaling cascades in mammalian cells.30 In addition, supramolecular assemblies built from 
designed CCs have been developed as potential delivery and vaccine platforms for both 
bacterial and eukaryotic systems.31-36 These reports highlight just some of the possibilities of 
taking de novo protein modules and PPIs from in vitro settings into living cells. 
Here, we test the capacity of a sample set of our de novo designed CC peptides to 
function as PPI domains in a range of contexts within living E. coli cells. We show that our 
homo and hetero-dimeric CC peptides can mediate PPIs in multiple systems in vivo, including 
as part of a cytoplasmic split enzyme, and as components of both transcription repressors and 
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transcription activators. In most cases, the binding affinity designed and measured in vitro is 
reflected in the strengths of the regulatory activity measured in vivo. The heterodimeric 
sequences show the expected specificity, with little or no self-association or off-target activity 
evident. To demonstrate the complete modular design of synthetic transcription factors, we 
combine the de novo CC-based PPIs with programmable DNA-binding domains based on TAL 
repeats to generate homo- and heterodimeric transcription regulators. Thus, in these artificial 
transcription factors, both PPI activity and DNA-binding activity can be designed to match the 
requirements of a desired application. 
 
RESULTS AND DISCUSSION 
Protein Colocalization In Vivo by De Novo Designed PPIs.  First, we measured the ability 
of our toolkit of CC peptides to bring together the components of a split cytoplasmic enzyme. 
In this system the adenylate cyclase protein of Bordetella pertussis is expressed as two separate 
domains (T25 and T18), which come together to form an active enzyme when fused to partner 
proteins that form a PPI.37 This reconstitution produces cyclic AMP (cAMP), which is detected 
by monitoring the production of a lacZ reporter gene regulated by the cAMP receptor protein 
(CRP) (Figure 1a). 
We tested two de novo CC PPIs: the homodimeric CC-Di 23 and the heterodimer CC-
Di-AB system, in which complementary CC-Di-A and CC-Di-B peptides have been made with 
3-, 3.5- and 4- heptad repeats.24  Plasmids encoding these CC peptides fused to the C termini 
of the components of split adenylate cyclase (i.e., the T25 and T18 domains) were constructed 
using sequences codon-optimized for expression in E. coli (Figure 1b and Table S2). 
Reconstitution of adenylate cyclase was monitored in an E. coli strain DMH1.1, which lacks 
the native adenylate cyclase gene (cya-). T25 and T18 fusions were co-expressed, and 
expression of β-galactosidase from the cAMP-dependent lacZ gene was monitored by the 
production of a blue colony phenotype when the transformants were grown on rich X-gal 
indicator agar. 
Cells expressing T25 and T18 without fusion partners did not produce detectable β-
galactosidase (Figure 1c), and a positive control with these components fused to the yeast 
GCN4 leucine zipper produced cells with a blue phenotype. The leucine zipper could be 
substituted both by the CC-Di homodimer and by the CC-Di-AB pairs to give the blue 
phenotype indicative of adenylate cyclase reconstitution. Moreover, the heterodimers produced 
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a graded effect on phenotype: a strong blue phenotype was observed in strain DHM1.1 when 
both peptide sequences were at least 3.5 heptads long and reduced or no coloration seen when 
either partner was just 3 heptads long. The experiments were repeated in another cya- strain, 
BTH101, which is reported to be more sensitive to weak interactions (Figure 1c). In this strain 
a positive interaction in cells expressing CC-Di-B3 in conjunction with CC-Di-A3.5 or CC-Di-
A4 was more evident, although the intensity of the blue phenotype was reduced in all cases 
compared to DHM1.1. 
These results indicate that the homodimeric CC-Di and the heterodimeric CC-Di-AB 
pairs form PPIs within the cellular environment when expressed as fusions to a split 
cytoplasmic enzyme.  
Transcription activation in vivo by de novo designed PPIs. The graded phenotype of the 
heterodimeric adenylate cyclase constructs suggests that the binding affinities designed and 
measured in vitro are reflected in the strength of interaction in vivo. However, this adenylate 
cyclase assay is only semi-quantitative as it contains a positive feedback loop (expression of 
the fusion proteins is increased by the production of cAMP). To test the behavior of the CC-Di 
peptide sequences in a more quantitative system, next we determined their ability to drive 
transcription activation in a bacterial 2-hybrid system.  
Arbitrary PPIs can activate transcription via recruitment of RNA polymerase when one 
interacting partner is fused to a sequence-specific DNA binding domain (DBD) and the other 
is fused to RNA polymerase.14 To test the de novo CCs as transcription-activating interfaces 
we used a bacterial 2-hybrid system comprising the λcI repressor protein as the DBD and a 
truncated α subunit of RNA polymerase as the target for recruitment (Figure 2a).38  CC-Di, 
CC-Di-A or CC-Di-B sequences were fused to the C termini of the truncated α subunit and the 
DBD. The ability of combinations of these constructs to activate transcription was monitored 
in a reporter strain carrying a lacZ reporter gene under the control of a synthetic promoter with 
an upstream λcI binding site. 
The homodimeric CC-Di fusions did not activate gene expression in this system 
(Supplementary Figure S1). This is not surprising as both λcI and the α subunits are themselves 
dimers, so we expect in cis CC homodimerization to be favored over in trans DBD-target 
interactions. It is also possible that the homodimeric CC-Di sequences enable interactions 
between two λcI dimers or two RNA polymerases to compete with productive DBD-target 
interactions. By contrast, all the CC-Di-AB combinations activated transcription, regardless of 
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which of the AB pairing was fused to the α subunit and which was fused to the DBD (Figure 2 
b and c). Activation depended on the presence of a cognate binding partner (Supplementary 
Figure S1), and in any given orientation the degree of activation increased with the length of 
the PPI for combinations of sequences containing 3 and 3.5 heptad repeats. Activation by CC-
Di-AB combinations in which one or both partners contained a 4-heptad repeat showed less 
predictable levels of transcription activation. At present we cannot offer a clear explanation of 
this.  The nature of the CC sequence fused to λcI or the α subunits did not cause notable changes 
in the expression levels of the proteins (Supplementary Figures S1 and S2). Therefore, the 
unexpected behavior of the 4 heptad constructs may reflect competition between on-target 
heterodimerization and off-target homodimerization of these longer CCs in a manner similar 
to that seen with CC-Di; indeed, we note that CC-Di-B4 shows weak homodimerization in 
vitro.24 This unexpected complexity highlights the need for some empiricism in the use of these 
de novo designed systems. Nonetheless, it is clear that gene activation can be directed by these 
de novo designed heterodimeric PPIs in vivo. 
Transcription repression in vivo by de novo designed PPIs.  The E. coli Lac repressor (LacI) 
is a “dimer of dimers”, with the primary dimer interfaces between monomer surfaces and 
tetramerization mediated by C-terminal regions of each monomer, which form an antiparallel 
four-helix CC bundle.39 Dimerization enables the repressor to bind tightly to a palindromic 
operator sequence, and tetramerization enables simultaneous binding to a second, auxiliary 
operator.40 The CC region can be replaced by the GCN4 leucine zipper, converting the 
tetrameric protein into an active dimer.39 Similarly, we replaced the wild-type CC with our de 
novo designed CC dimers (Figure 3a). To maximize the reliance of dimerization on interaction 
of our CC sequences, we used a C-terminally truncated LacI variant with a weakened 
monomer-monomer interface (LacI*).41 
The de novo CCs were fused via short linkers to the C terminus of LacI*. Genes 
encoding full length LacI or the LacI* proteins, with N-terminal His-tag and XpressTM tags, 
were expressed under the control of the arabinose-inducible PBAD promoter. Activity of the 
resulting fusion proteins was tested in a lacI- strain using a superfolder GFP reporter under the 
control of the lacUV5 promoter, which carries a single lac operator sequence (Figure 3a). GFP 
expression was greatly reduced in cells expressing full length LacI protein, but only slightly 
reduced in cells expressing LacI* (Figure 3b). GFP expression in cells expressing LacI*-CC-
Di was similar to that observed with full length LacI, indicating that CC-Di can substitute for 
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the WT CC sequence to drive oligomerization of the repressor protein and consequent binding 
to DNA.  
Next, we measured the effect of forming LacI* heterodimers mediated by the tunable 
CC-Di-AB series. The LacI*-CC-Di-A and LacI*-CC-Di-B constructs were expressed from 
different plasmids, each under the control of the PBAD promoter. Co-expression of LacI* 
proteins fused to CC-Di-A3.5 and CC-Di-B3.5 resulted in a level of repression intermediate 
between full-length LacI and LacI* (Figure 3c). This effect requires a complementary partner 
sequence: neither LacI*-CC-Di-A3.5 or LacI*-CC-Di-B3.5 increased repression compared to 
LacI* when expressed without its partner. Notably, the series of CC-Di-AB fusion proteins 
repressed expression of GFP in line with the affinities of the CC heterodimers measured in 
vitro (Figure 3d).24  For example, cells expressing LacI*-CC-Di-B3.5 showed stronger 
repression when co-expressed with a fusion partner carrying a 3.5-heptad CC-Di-A sequence 
than they did when paired with a 3-heptad variant, and the level of repression increased further 
when the 4-heptad CC-Di-A sequence was used. The pattern of increased repression with 
increasing predicted strength of CC interaction was observed with all of the tested 
combinations, with the strongest repression being observed with the pairing of the two 4-heptad 
repeat sequences. 
These results confirm that the homodimeric CC-Di and the heterodimeric CC-Di-AB 
modules can function as PPIs to mediate the affinity of dimerization of transcriptional 
repressors in vivo in a predictable and tunable fashion.  
Oligomerization of TAL-based repressors by de novo designed PPIs.  To create truly 
orthogonal synthetic transcription repressors it is desirable to couple designed PPIs with 
designable DBDs. CRISP-Cas9, Zn-fingers and TAL repeats have all been used to direct 
protein binding to specific sites on DNA within cells.42, 43  TAL effector proteins (TALEs) 
contain tandem arrays of ≈34-residue TAL-repeat DBDs, each of which recognizes a single 
target base in DNA.44  Site-specific DNA binding proteins can thus be built by assembling 
appropriate combinations of these TAL repeats. As a step towards creating wholly designed 
systems in which the specificity and affinity of both protein-protein and protein-DNA 
interactions can be specified, we combined our de novo CC-based PPIs with engineered TAL-
based DBDs to create tunable homodimeric and heterodimeric transcription factors.  
In their natural context the arrays of TAL repeats are flanked by N- and C-terminal 
regions that appear to be important for function in mammalian cells.45 To identify the minimal 
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TAL repeat scaffold that can serve as a DBD in our bacterial system, we designed a series of 
TAL-repeat proteins to bind to the lacO1 operator sequence; namely, (I) a full-length TALE 
protein with intact N- and C-terminal regions, and truncated proteins lacking (II) the C-terminal 
region, (III) the N-terminal region, or (IV) both. These were expressed from the PBAD promoter, 
and their ability to bind DNA in vivo was assessed with a GFP reporter gene expressed from 
the lacUV5 promoter carrying a single copy of lacO1 (Figure 4). Construct I repressed the 
reporter gene efficiently at basal and induced levels of expression. Construct IV produced no 
repression at any level of expression tested. Construct III showed substantially impaired 
repression, although some function was retained. In contrast, although construct II was less 
effective than the full-length protein it did repress transcription effectively when its expression 
was induced. 
As the C-terminal region of the TALE protein is not essential for DNA binding function 
in bacteria, we fused the homodimeric CC-Di peptide sequence via a short linker to the C 
terminus of a 17-repeat TAL array that was designed to bind to the lacO1 sequence and that 
retained the native N-terminal region (TALX). Dimeric TALE-based proteins can loop DNA, 
enhancing the efficiency of repression.12 Therefore, we tested the ability of this construct to 
repress transcription from lacUV5 promoters carrying either one or two lacO1 sequences. Each 
contained a “primary operator” that overlapped the transcription start site, and the second 
operator, when present, was placed 92 bp upstream of the primary operator (Figure 5a). Control 
experiments with wild-type tetrameric LacI confirmed that the presence of the auxiliary 
upstream lacO1 promoter enhanced repression in our system (Figure 5b). TALX lacking CC-
Di repressed transcription from the single and dual operator promoters equally, but repression 
by TALX-CC-Di was enhanced by the presence of the upstream operator. This enhancement 
was abolished when the sequence of the upstream operator was changed from that of lacO1 to 
the related but distinct sequence, lacO3. These results suggest that TALX-CC-Di forms a dimer 
in vivo that, by looping DNA, can bind cooperatively to two specified DNA sites. 
Heterodimerization of TAL constructs should allow looping between two different 
DNA sequences, and also offer the possibility of integrating multiple regulatory signals to 
control the expression of each partner. To test this, we combined TAL constructs with the CC-
Di-AB heterodimerization system. We designed a second 16 repeat TAL array, which retained 
the native N-terminal region and bound a target site that was not recognized by TALX (TALY) 
(Supplementary Figure S3). We fused CC-Di-B4 via a short linker to the C terminus of TALX 
and CC-Di-A4 via a short linker to the C terminus of TALY. Then, we tested the effect of 
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combinations of constructs on expression from lacUV5 promoters carrying the TALY binding 
site as a primary operator and lacO1 or lacO3 as the secondary operator (Figure 6). Co-
expression of TALY-CC-Di-A4 and TALX-CC-Di-B4 enhanced repression when the auxiliary 
operator was lacO1. This enhancement was lost when the upstream site was mutated to lacO3, 
or when the PPI was abolished by omission of the CC-Di-A/B peptide from TALX or TALY. 
These results indicate that combining TAL repeat sequences with de novo designed 
PPIs allows the design of proteins with desired protein-DNA and protein-protein interaction 
specificity that function within living cells.  
Conclusion. The ability to direct and control the assembly of macromolecular complexes in 
cells is a key aim of synthetic biology. For instance, building networks of interacting 
components could allow engineered cells to colocalize or to segregate cellular processes, and 
to respond to their environment in complex but predictable ways. Herein, we show that 
straightforward de novo designed protein-protein interactions (PPIs) can substitute for natural 
PPIs to complement fragments of enzymes and to control transcriptional processes in bacterial 
cells.  In addition, by combining these de novo PPIs with engineered DNA-binding repeats, we 
generate completely new transcriptional repressors.  Moreover, because of the designability of 
the de novo PPIs, the degree of downstream activity can be tuned. These de novo and 
engineered modules expand the repertoire of components for synthetic biology and protein 
design in the cell. 
The construction of Gene Regulatory Networks (GRNs) is one area where multiple 
orthogonal and tunable PPIs of the type we describe are needed. In this field, transcription 
repressors and activators, together with their DNA targets, are organized in topologies that 
enable cells to undertake computational tasks and actuate appropriate responses.46, 47 Some of 
the most-complex GRNs have been built in E. coli, where a wide range of well-characterized 
native components is available. However, as the complexity of the networks increases the use 
of endogenous regulatory components becomes limiting. Many of the existing GRN sub-
systems reuse the same small set of transcription factors, such as the LacI and TetR 
repressors.48, 49 Therefore, they cannot be combined readily as cross-talk between different 
parts of the network is inevitable. The range of characterized components available for use in 
GRNs can be increased either by co-opting regulatory components from other organisms, or 
by creating novel components. An example of the first approach is a library of mutually 
orthogonal repressors composed of TetR proteins from diverse prokaryotic species.50 New 
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components can also be created by modifying existing natural systems to modify their 
properties and make them orthogonal; for example, mutation of the bacteriophage T7 RNA 
polymerase has been used to generate a library of orthogonal RNA polymerases that recognize 
different promoter sequences.51 In addition, transcription regulators represent an attractive 
target for de novo protein design, which was part of the motivation for the work presented 
herein. 
Here we show that our de novo CC-based PPIs designed from first principles can 
mediate the function of both transcription activators and repressors. Furthermore, these de novo 
PPIs can be combined with engineered TAL DNA-binding repeats to produce transcription 
repressors in which the affinity and specificity of both protein-protein and protein-DNA 
interactions are specified.  This offers possibilities for creating components with specificities 
and affinities that are optimized on the basis of the mathematical model of a desired GRN, 
avoiding the limitations of natural components that have evolved for other purposes.  
We have explored the function of a toolkit of designed homo- and heterodimeric CCs 
in four different molecular contexts in E. coli cells.  We find that in most cases the CC behavior 
mirrors that seen in vitro. Some of the peptide sequences tested here have been shown recently 
to assemble in E. coli in other contexts: the heterodimeric CC drives the assembly of a novel 
cytoscaffold and the subcellular localization of active enzymes when fused to shell proteins of 
a bacterial microcompartment;6, 7 and, while the work presented here was in preparation, the 
same heterodimeric CCs have been shown by others to recruit T7 RNA polymerase to Zn-
finger DNA-binding domains.28 Some adverse context-dependent effects have been noted: in 
our activation experiments proximity effects may inhibit heterodimerization; and in the 
programmable T7 RNA polymerase system the hierarchy of CC interaction strength varies with 
the nature of the Zn-finger domains to which the peptides are fused.28 Thus, it is likely that 
improved rules or methods for designing linker sequences will be needed to help minimize 
such effects in future applications. We are working on this challenge using the ISAMBARD 
suite for computational protein design.52, 53  Nonetheless, our results, together with those of 
others,26, 28 indicate that the rules used to design our peptide sequences are sufficiently 
comprehensive to allow the CC components of the sequences to interact as designed in a 
cellular environment. Although we have yet to probe these systems with proteomics, it appears 
that the introduced biomolecular interactions operate orthogonally to the endogenous E. coli 
proteome and interactome.  The dimeric CCs employed in this work are part of a much larger 
set of CCs that have been designed on similar principles and have been fully characterized in 
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vitro.54, 55 These include designs of varying affinities, geometries and oligomerization states, 
from dimers through to octamers. Therefore, this work provides a starting point for the design 
and implementation of more-complex higher-order PPIs and possibly regulatable PPIs for 
control of protein assembly within cells. 
 
MATERIALS AND METHODS 
Plasmids. Full details of the construction of the plasmids used in this work are given in the 
supplementary information. Briefly: Adenylate cyclase reconstitution assays used derivatives 
of plasmid pKT25 (kanR), which encode fusions to the T25 fragment of Bordetella pertussis 
adenylate cyclase (CyaA) (amino acids 1-224) and of plasmid pUT18c (ampR), which encode 
fusions to the T18 fragment of CyaA (amino acids 225-399).56, 57 Transcription activation 
assays used derivatives of pRA02 (ampR), which encodes fusions with the -subunit of RNA 
polymerase (amino acids 1-248), and of pRA03 (cmR) which encodes fusions with the λcI 
protein (amino acids 1-236)58. Lac repressor protein fusions were expressed from derivatives 
of plasmid pBADLacI* (ampR) or pVRcLacI* (cmR) which encode a C-terminally truncated 
Lac repressor (amino acids 1-331) containing an L251A substitution, under the control of the 
arabinose inducible araBAD promoter. Fusions to TAL repeats were expressed from plasmids 
derived from pVRc20_992 (cmR, a gift from Christopher Voigt, Addgene #4973959) or 
pBADHis-B-iRFP (a gift from Vladislav Verkhusha, Addgene plasmid #3185560), under the 
control of the arabinose inducible araBAD promoter. The reporter plasmid pVRbLacUV5 
(kanR) and derivatives allow the expression of sfGFP from the lacUV5 promoter and is derived 
from the plasmid pVRb20_992 (kanR, a gift from Christopher Voigt, Addgene plasmid 
#4971459). 
Bacterial two-hybrid assay utilizing adenylate cyclase reconstitution. The bacterial two-
hybrid assay based on adenylate cyclase reconstitution described in this work is essentially that 
described by Battesti and Bouveret.56 cya- DHM1.1 or BTH101 cells56 were transformed with 
both pUT18c and pKT25 derived plasmids containing the adenylate cyclase subdomains T18 
or T25 fused to different CC peptides.  Cells were grown at 30°C on LB agar supplemented 
with 100 g/ml ampicillin and 50 g/ml kanamycin.  Overnight cultures were diluted in LB to 
an OD600=1 and 2 l of each culture was spotted onto LB agar + 100 g/ml ampicillin + 50 
g/ml kanamycin + 0.5 mM IPTG + 40 g/ml X-gal.  Plates were incubated at 30°C for 24 
hours (BTH101) or 48 hours (DHM1.1). 
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Bacterial two-hybrid assay utilizing transcription activation. The transcription activation 
based bacterial two-hybrid assay described here is essentially that developed by Dove and 
Hochschild.38 Reporter strain KS114 contains a lacZ gene on the chromosome with a promoter 
that can be activated by interactions between a peptide fused to λcI and a peptide fused to the 
α-subunit of RNA polymerase. KS1 cells were transformed with pRA02 and pRA03 or their 
derivatives and grown at 37°C on LB agar supplemented with 100 g/ml ampicillin, 50 g/ml 
kanamycin and 25 g/ml chloramphenicol. Colonies were picked in triplicate and overnight 
cultures were grown at 37°C.  These were used to inoculate 10 ml LB + 100 g/ml ampicillin 
+ 50 g/ml kanamycin + 25 g/ml chloramphenicol + 20 M IPTG.  Cultures were grown at 
37°C until they reached an OD600 ~0.5.  β-galactosidase activity of each culture was assayed in 
duplicate in 96-well plates after lysis by PopCulture lysis reagent (Novagen) essentially as 
described by Thibodeau et al.61  The change in A405 at 30°C was measured over 30 minutes at 
1 minute intervals in a Spectramax plate reader (Molecular Devices) and the rate of change of 
the A405 was normalised by dividing by the OD600 of the cell culture. 
GFP assays. To monitor repression of transcription TB28 cells (MG1655LacIZYA62) were 
transformed with pVRbLacUV5 reporter plasmid or its derivatives, and plasmids expressing 
Lac repressor or TALE fusion proteins as indicated.  Colonies were picked in at least triplicate 
and overnight cultures were grown at 37°C in M9 minimal media + 0.25% glycerol + 0.5 mM 
CaCl2 + 2 mM MgSO4 + 2 g/ml thiamine + 0.2% casamino acids (+ 50 g/ml kanamycin + 
100 g/ml ampicillin + 25 g/ml chloramphenicol where required).  The overnight cultures 
were used to inoculate 10 ml of the same medium and cultures were grown at 37°C until they 
reached an OD600~0.5.  Where indicated arabinose was added to the 10 ml cultures at the 
concentrations indicated: where no arabinose was added the fusion protein expression resulted 
from basal transcription from the araBAD promoter.  5 ml of culture was centrifuged and the 
pellet was resuspended in 250 l PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4).  2 x 100 l cell suspension from each culture was placed in a black, flat bottomed 
96 well plate and the fluorescence read in a FLEXstation plate reader (Molecular Devices).  
The excitation wavelength was 470 nm and the emission wavelength was 510 nm with a cut-
off of 495 nm.  GFP fluorescence (relative fluorescence units) was normalised by dividing by 
the OD600.  
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FIGURE LEGENDS  
Figure 1. De novo designed PPIs interact in vivo.  (a) The T25 and T18 domains of B. pertussis 
adenylate cyclase can be reconstituted in the presence of interacting CC peptides and this 
positively regulates expression of -galactosidase. (b) Fusion proteins used in this assay.  The 
T25 or T18 subdomains are fused to CCs via a short linker.  CCs are labelled as follows: Zip, 
leucine zipper of the yeast GCN4 protein; CC-Di, homodimeric coiled coil; CC-Di-Ax and CC-
Di-Bx, acidic or basic heterodimeric CCs comprising x heptad repeats.  (C) The cya- E. coli 
stains DHM1.1 and BTH101 were transformed with pairs of fusion proteins as indicated and 
cultures were spotted on LB agar containing X-gal + IPTG.  Blue coloration indicates 
production of -galactosidase.  The horizontal labels indicate T18-CC-Di-A fusions and the 
vertical labels indicate T25-CC-Di-B fusions. 
Figure 2.  Activation of gene expression with de novo designed PPIs.  (a) In this assay one CC 
peptide is fused to the CI protein and the other is fused to the NTD of the  subunit of RNAP.  
Formation of a CC recruits RNAP to the lac promoter which activates transcription of -
galactosidase.  (b & c) Bar charts of -galactosidase activity of cells expressing fusion proteins 
containing different combinations of the 3-, 3.5- and 4-heptad repeat heterodimeric CC 
peptides.  The acidic coils (CC-Di-A) were fused to the -NTD and the basic coils (CC-Di-B) 
were fused to cI, and vice versa.  -galactosidase activity was normalized to the OD600 of the 
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bacterial cell culture and is the average of activity from three different cultures shown with 
standard error. 
Figure 3. Repression of transcription mediated by interaction of de novo designed PPIs.  (a) 
CC peptides were fused to LacI*, a dimerization mutant of Lac repressor.  If interaction of the 
CC peptides occurred LacI* was able to bind to lacO1 and repress transcription of GFP.  (b) 
Bar chart showing repression of GFP activity mediated by the interaction of homodimeric 
coiled coil peptides (CC-Di) fused to LacI*.  (c) Bar chart of GFP activity when LacI* was 
fused to either an acidic or basic 3.5 heptad repeat heterodimeric CC peptide (CC-Di-A3.5 or 
CC-Di-B3.5) and assayed in the combinations indicated.   (d)  Bar chart showing repression of 
GFP activity of cells expressing LacI* fusion proteins containing different lengths of the 
heterodimeric CC peptides CC-Di-A and CC-Di-B.  GFP fluorescence was normalized to the 
OD600 of the cell culture and is an average of three repeats shown with standard error.    
Figure 4. Repression of GFP activity by full-length and truncated TALE proteins.  Cells were 
transformed with plasmids expressing either a full-length TALE (I), or derivatives lacking the 
C-terminal region (II), the N-terminal region (III) or both the N- and C-terminal region (IV).  
N: N-terminal region. R: TAL repeat region. C: C-terminal region. Arabinose was added to the 
cells at the concentrations indicated in order to induce expression of the TAL protein.  GFP 
fluorescence was normalized to the OD600 of the cell culture and is an average of three repeats 
shown with standard error. 
Figure 5. Repression of GFP activity by de novo homo-dimeric TAL-CC fusion proteins.  (a) 
CC-Di was fused to TALX which binds the lacO1 operator. Three GFP reporter plasmids were 
used in which there was (i) one lacO1 site at the promoter, (ii) two lacO1 sites 92 bp apart, and 
(iii) the upstream binding site was changed to the operator sequence lacO3. (b) Bar chart 
showing GFP activity of cells expressing the GFP reporter plasmid and the repressor construct 
indicated. Repression of GFP was enhanced when two binding sites for TALX were present 
and the repressor protein was able to dimerize via CC-Di. GFP fluorescence was normalized 
to the OD600 of the cell culture and is an average of three repeats shown with standard error.    
Figure 6. Repression of GFP activity by de novo heterodimeric TAL-CC fusion proteins.  (a) 
CC-Di-A4 was fused to TALY and CC-Di-B4 was fused to TALX. (i) A GFP reporter plasmid 
was used in which there was a TALY binding site at the promoter and a lacO1 site 92 bp 
upstream.  (ii) An additional reporter plasmid was used where the upstream binding site was 
changed to the lacO3 sequence. (b) Bar chart of GFP activity of cells transformed with a GFP 
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reporter plasmid and two additional plasmids expressing the TALX and TALY fusion proteins 
as indicated.    Repression of GFP was enhanced when binding sites for TALX and TALY were 
present and the repressor protein was able to dimerize via CC-Di-A4B4 interactions.  GFP 
fluorescence was normalized to the OD600 of the cell culture and is an average of three repeats 
shown with standard error.    
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Plasmid construction 
The CC sequences and corresponding DNA sequences used in this work are shown in table S2.  
A short linker was encoded upstream of each CC peptide (table S3), and XbaI and Acc65I 
restrictions sites at each end facilitated cloning in frame with the C-terminal end of the various 
proteins used in this work. The DNA fragments encoding CC-Di-A3.5, CC-Di-B3.5 and CC-Di 
were synthesised as GeneStrings (GeneArt, Invitrogen).   DNA sequence encoding CC-Di-A3, 
CC-Di-B3, CC-Di-A4 and CC-Di-B4 were produced by removing (CC-Di-A3, CC-Di-B3) or 
adding (CC-Di-A4, CC-Di-B4) sequences from/to expression vectors containing the 3.5 heptad 
CC sequences using PCR. 
Plasmid pKT25 (kanR) encodes the T25 fragment of Bordetella pertussis adenylate cyclase 
(CyaA) (amino acids 1-224) and plasmid pUT18c (ampR) encodes the T18 fragment of CyaA 
(amino acids 225-399).1, 2 Both fragments are expressed from the PLac promoter. The synthetic 
DNA fragments encoding the CC peptides were cloned in frame downstream of the T25 or T18 
subdomains at XbaI/Acc65I sites to make pKT25-CC-Di, pUT18c-CC-Di, pKT25-B3.5 and 
pUT18c-A3.5.  Plasmids pKT25-zip and pUT18c-zip encode the T25 and T18 fragments fused 
to the yeast GCN4 leucine zipper.2 
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For the transcription-activation based bacterial two-hybrid assay the DNA fragments encoding 
the CC peptides were cloned into either pRA02 (ampR), which encodes fusions with the -
subunit of RNA polymerase (amino acids 1-248), or pRA03 (cmR) which encodes fusions with 
the λcI protein (amino acids 1-236)3.  DNA fragments encoding the CC peptides CC-Di-A3.5, 
CC-Di-B3.5 and CC-Di were inserted into the XbaI/Acc65I sites of both pRA02 and pRA03 
allowing in-frame fusions with the α-subunit or λcI. 
Plasmid pBADLacI (ampR)  was made as follows: DNA encoding WT Lac repressor protein 
(LacI) was amplified by PCR from pET21a (Novagen) and was cloned into pBADHis-B-iRFP 
(a gift from Vladislav Verkhusha, Addgene plasmid #318554) at BglII/HindIII sites.  
pBADLacI allows expression of LacI from the arabinose inducible PBAD promoter, giving an 
N-terminal 6xHis tag and XpressTM epitope tag.  Plasmid pBADLacI* encodes a truncated LacI 
gene (aa 1-331) containing an L251A substitution which was introduced by site-directed 
mutagenesis.  XbaI and Acc65I sites were introduced downstream of the truncated LacI gene, 
allowing DNA encoding CC-Di and CC-Di-B peptides to be cloned in frame at the C terminus 
of LacI*.  In order to express heterodimeric LacI-CC peptide fusion proteins an additional set 
of cmR plasmids were made containing a different origin of replication.  The lacI* gene, PBAD 
promoter and araC gene were excised from pBADLacI* at BsaI/NsiI restriction sites and 
cloned into pVRc20_992 (a gift from Christopher Voigt, Addgene #497395) to produce 
pVRcLacI*.  DNA fragments encoding CC-Di-A peptides were cloned into pVRcLacI* at 
XbaI/Acc65I sites. The p15A ori in pVRcLacI* has a lower copy number than the pBR322 ori 
in pBADLacI* which lacks the rop gene6 so the expression levels of LacI*-CC-Di-A and 
LacI*-CC-Di-B are expected to vary slightly. 
TALE DNA binding domain arrays were constructed using the Joung lab REAL assembly 
TALEN kit, a gift from Keith Joung (Addgene kit # 10000000177).  This kit allows the 
production of DNA fragments encoding TALE repeat arrays using sequential restriction 
enzyme digestion and ligation.  The DNA binding sites of the TALEs used in this work are 
shown in table S4.  pBAD-His-JDS78 (ampR) contains the N- and C-terminal domains of the 
TALE and also the 0.5 TAL repeat which is at the C-terminal end of the TALE repeat array, 
and was made by PCR amplification of a DNA fragment encoding the TALE N and C terminus 
and the T 0.5 repeat from the plasmid JDS78 (from Addgene kit # 1000000017). This fragment 
was cloned into the BglII /HindIII sites of a pBAD-His-iRFP derivative in which the BsmBI 
site was mutated, creating pBAD-His-JDS78.  Sequence encoding a TAL repeat array 
recognising 16 bp of the lacO1 sequence constructed by REAL assembly (TALA) was inserted 
 3 
 
into pBAD-His-JDS78 at the BsmBI site to create pBADTALA (Construct I; TALA aa 1-763). 
In order to examine the minimal TAL domains required for DNA binding the TALA repeat 
array (R) was also inserted into the vectors pBAD-His-JDS78CTD (Construct II; TALA aa 
1-707), pBAD-His-JDS78NTD (Construct III; TALA aa 129-763) and pBAD-His-
JDS78NTD+CTD (Construct IV; TALA aa 129-707). These contained different 
combinations of the TALE N- and C-terminal regions and were created by PCR amplification 
from JDS78 and insertion into pBAD-His-RFP.   
Plasmid pBAD-His-JDS78XA  contains the N-terminal domain of the TALE and the T 0.5 
repeat (but not the C-terminal domain) and was constructed by PCR using primers that added 
an XbaI site and Acc65I site downstream of the 0.5 TAL repeat.  A sequence encoding a TAL 
repeat array recognising 17 bp of the lacO1 sequence (TALX) was inserted into pBAD-His-
JDS78XA to create pBADTALX, and then sequences encoding the CC peptides CC-Di and 
CC-Di-B were cloned in frame with at the C-terminal end to produce pBADTALX-CC-Di and 
pBADTALX-CC-Di-B. To express heterodimeric TAL-CC peptide fusion proteins an 
additional set of plasmids with an alternative ori and marker were constructed. A BsaI/NsiI 
fragment from pBAD-His-JDS78XA containing the araC gene and the expression cassette 
encoding the N-terminal domain of the TALE and the T 0.5 repeat was inserted into 
pVRc20_992 to produce pVRcJDS78XA. A sequence encoding a TAL repeat array 
recognising 16 bp of non-lacO sequence (TALY) was inserted into pVRcJDS78XA as above 
to create pVRcTALY. DNA fragments encoding CC-Di-A peptides were inserted at 
XbaI/Acc65I sites to produce pVRcTALY-CC-Di-A.  
The reporter plasmid pVRbLacUV5 (kanR) allows the expression of sfGFP from the lacUV5 
promoter and is derived from the plasmid pVRb20_992 (a gift from Christopher Voigt, 
Addgene plasmid # 497145).  DNA containing the lacUV5 promoter minus the CRP half site 
(-53/+40) was amplified from the plasmid pSRLacUV58 by PCR and was cloned into 
pVRb20_992 at BspHI and BamHI sites. For experiments analysing repression by TAL-CC 
fusion proteins the following reporter plasmids were created by modifying pVRbLacUV5: 
pVRblacO1-lacO1, pVRblacO1-lacO3, pVRbTALY-lacO1, pVRbTALY-lacO3. Details of 
the promoter region of these reporter constructs is shown in table S5.  Synthetic DNA 
fragments carrying the promoters containing binding sites for TALX (lacO1) and TALY, and 
the lacO3 operator sequence were inserted into pVRbLacUV5 at EcoRI/HindIII sites.  The 
spacing between the operator sequences is identical to the wild type lac promoter (92 bp). 
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Western blotting  
To detect expression of coiled coil peptide fusion proteins, bacterial cultures were lysed in 
SDS-loading buffer (100 mM Tris-Cl pH 6.8, 4% (w/v) SDS, 0.2 % (w/v) bromophenol blue 
20% (v/v) glycerol, 200 mM DTT) and samples corresponding to equivalent amounts of cells 
were run on an SDS–polyacrylamide gel of an appropriate percentage.  Protein was transferred 
onto an immobilonP PVDF membrane (Millipore). Membranes were probed with polyclonal 
anti- subunit antibodies (a gift from A. Ishihama), anti-CI antibodies (a gift from A. 
Hochschild) or a monoclonal antibody against the His-tag (BD-biosciences #631212) using 
standard western blotting techniques. Detection was carried out using the POD 
chemiluminescence system (Roche). 
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 CC-Di-A3 CC-Di-A3.5 CC-Di-A4 
CC-Di-B3 (3.10 ± 0.58) × 10-6 (2.79 ± 1.42) × 10-7 (7.47 ± 3.30) × 10-8 
CC-Di-B3.5 (6.40 ± 2.77) × 10-7 (5.15 ± 2.05) × 10-9 (2.08 ± 0.73) × 10-10 
CC-Di-B4 (3.87 ± 1.45) × 10-7 (4.74 ± 4.49) × 10-10 <1.0 × 10-10 
 
Table S1:  Kd values (M) of the heterodimeric CC pairs at 20 °C.  These were calculated from CD-thermal-denaturation experiments and are taken 
from 9 
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Construct Protein and DNA sequence 
CC-Di-A3 E  I  A  A  L  E  K  E  N  A  A  L  E  W  E  I  A  A  L  E  Q  G 
gaaattgctgcgctggagaaggagaatgcagccttggaatgggaaattgccgcactggaacagggg 
CC-Di-A3.5 L  E  Q  E  I  A  A  L  E  K  E  N  A  A  L  E  W  E  I  A  A  L  E  Q  G 
ctcgaacaggaaattgctgcgctggagaaggagaatgcagccttggaatgggaaattgccgcactggaacagggg 
CC-Di-A4 E  I  A  A  L  E  Q  E  I  A  A  L  E  K  E  N  A  A  L  E  W  E  I  A  A  L  E  Q  G 
gaaatcgctgcgctcgaacaggaaattgctgcgctggagaaggagaatgcagccttggaatgggaaattgccgcactggaacagggg 
CC-Di-B3 K  I  A  A  L  K  Y  K  N  A  A  L  K  K  K  I  A  A  L  K  Q  G 
aagatcgccgcactgaaatacaagaatgcggccctgaaaaagaagatcgcggcactgaaacagggt 
CC-Di-B3.5 L  K  Q  K  I  A  A  L  K  Y  K N  A  A  L  K  K  K  I  A  A  L  K  Q  G 
ctgaaacagaagatcgccgcactgaaatacaagaatgcggccctgaaaaagaagatcgcggcactgaaacagggt 
CC-Di-B4 K  I  A  A  L  K  Q  K  I  A  A  L  K  Y  K N  A  A  L  K  K  K  I  A  A  L  K  Q  G 
aagattgctgcgctgaaacagaagatcgccgcactgaaatacaagaatgcggccctgaaaaagaagatcgcggcactgaaacagggt 
CC-Di E  I  A  A  L  K  Q  E  I  A  A  L  K  K  E  N  A  A  L  K  W  E  I  A  A  L  K  Q  G 
gaaattgctgcgctgaaacaggaaatcgctgccctgaaaaaagagaatgccgctctgaaatgggaaatcgcagcgctgaaacaaggt 
 
Table S2:  The amino acid sequences of the CC peptides used in this work9, 10.  Below is the DNA sequence which was designed using codons 
selected for expression in E. coli. 
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Construct Linker Sequence 
pKT25-CC-Di-B† AGSTGSESG 
pUT18c-CC-Di-A† SGGSTGSGGSG 
pKT25-CC-Di AGSTLEGSG 
pUT18c-CC-Di HCRSTLEGSG 
pRA02-CC-Di-A, pRA02-CC-Di-B, pRA02-CC-Di ALEGSG 
pRA03-CC-Di-A, pRA03-CC-Di-B, pRA03-CC-Di AALEGSG 
pBADLacI*-CC-Di, pBADLacI*-CC-Di-B, pVRcLacI*-CC-Di-A APGLEGSG 
pBADTALX-CC-Di, pBADTALX-CC-Di-B, pVRcTALY-CC-Di-A SIVAQLSGLEGSG 
 
Table S3: Plasmids used in this study and the linker sequences between the protein domains and the C-terminal CC peptides.  †These linker 
sequences were optimised by molecular dynamics modelling to allow optimal positioning of the CC and modified from the original sequence using 
site-directed mutagenesis. 
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TALE protein DNA sequence of binding site 
TALA TTGTGAGCGGATAACAAt 
TALX TTGTGAGCGGATAACAATt 
TALY TGATATGGAACAAAGCGt 
 
Table S4: DNA Binding sites for the TALE proteins used in this work.  The first T in bold is not bound by the TAL repeat array but is a requirement 
for TALE binding.  The lowercase t is recognised by the 0.5 TAL repeat present at the C-terminal end of each array.  
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Construct Promoter Sequence 
pVRbLacUV5 gaattccattaggcaccccaggctttacactttatgcttccggctcgtataatgtgtggaattgtgagcggataacaatttcacacaggaaacagcttgcgcaagctt 
 
pVRblacO1-lacO1 
 
gaattccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgaattgtgagcggataacaattaatgatcgtaagtggactcattaggcaccccaggctt
tacactttatgcttccggctcgtataatgtgtggaattgtgagcggataacaatttcacacaggaaacagcttgcgcaagctt 
 
pVRblacO1-lacO3 
 
gaattccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgatcgtaagtggactcattaggcaccccaggct
ttacactttatgcttccggctcgtataatgtgtggaattgtgagcggataacaatttcacacaggaaacagcttgcgcaagctt 
 
pVRbTALY-lacO1 
 
gaattccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgaattgtgagcggataacaattaatgatcgtaagtggactcattaggcaccccaggctt
tacactttatgcttccggctcgtataatgtgtggaatgatatggaacaaagcgtttcacacaggaaacagcttgcgcaagctt 
 
pVRbTALY-lacO3 
 
gaattccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgatcgtaagtggactcattaggcaccccaggct
ttacactttatgcttccggctcgtataatgtgtggaatgatatggaacaaagcgtttcacacaggaaacagcttgcgcaagctt 
 
 
Table S5: DNA sequences of the promoter regions of sfGFP reporter constructs.  EcoRI and HindIII restriction sites are underlined.  -35 and -10 
sequences of the LacUV5 promoter are in italics.  The TALX binding site (lacO1) is in bold, TALY is in bold and underlined and lacO3 is in bold 
and italics.   
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Supplementary figure S1. (a) Bar chart showing b-galactosidase activity of cells expressing 
fusion proteins containing CC-Di. Transcription activation is not observed with the 
homodimeric CC-Di. (b) Bar chart showing b-galactosidase activity of cells expressing fusion 
proteins containing CC-Di-A3.5 and CC-Di-B3.5.  Transcription activation only occurs when 
both peptides of the CC are present. b-galactosidase activity was normalised to the OD600 of 
the bacterial cell culture and is the average of activity from three different cultures shown with 
standard error of the mean.  (c & d) Western blots showing expression of fusion proteins in the 
assays shown in a & b.  Blots were probed with an antibody against the a-subunit of RNAP (* 
indicates the cellular a-subunit which is also recognised by the antibody) and an antibody 
against the lCI protein († shows the lCI fusion protein, the other bands are likely to be non-
specific products).  (c) Blot showing expression of fusion proteins from cultures assayed in (a).  
Lanes 1-3 are three separate cultures expressing a-NTD of RNAP and lCI protein alone.  
Lanes 4-6 are three separate cultures expressing a-NTD-CC-Di and lcI-CC-Di fusions. (d) 
Blot showing expression of fusion proteins from cultures assayed in (b). Each lane of the gel 
is cell lysate from one of the three cultures assayed.  CC-Di-A3.5 and CC-Di-B3.5 were fused to 
the a-NTD and to lcI in different combinations as indicated. 
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Supplementary figure S2. Western blots showing expression of fusions of the NTD of the α-
subunit of RNAP with CC-Di-A peptides, and the λCI protein with CC-Di-B peptides. Cells 
were grown in 50 ml cultures and were lysed by sonication. Equivalent proportions of the 
soluble (S) and insoluble (P) fractions were run on an SDS-PAGE gel and levels of the fusion 
proteins were analysed by western blotting.  Blots were probed with an antibody against the α-
subunit of RNAP (* indicates the cellular α-subunit which is also recognised by the antibody) 
and an antibody against the λCI protein († shows the λCI fusion protein, the other bands are 
likely to be non-specific products).   
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Supplementary figure S3.  Control for the experiments in figure 6, repression of GFP activity 
by de novo heterodimeric TAL-CC fusion proteins.  Bar chart showing GFP activity of cells 
transformed with GFP reporter plasmids and with a plasmid expressing single TALX or TALY 
fusion proteins as indicated.  Where shown CC-Di-A4 was fused to TALY protein and CC-Di-
B4 was fused to TALX protein.  GFP fluorescence was normalised to the OD600 of the cell 
culture and is an average of three repeats shown with standard error.    
